Effectiveness and Safety of Rituximab for Refractory Myasthenia Gravis: A Systematic Review and Single-Arm Meta-Analysis

Efficacy and safety of different dosages of rituximab for refractory generalized AChR myasthenia gravis: A meta-analysis

(2021) Ting Li et al.   JOURNAL OF CLINICAL NEUROSCIENCE

Differential response to rituximab in anti-AChR and anti-MuSK positive myasthenia gravis patients: a single-center retrospective study

(2020) Tess Litchman et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Rituximab in late-onset myasthenia gravis is safe and effective

(2020) Supreet K. Sahai et al.   MUSCLE & NERVE

Comparison Between Rituximab Treatment for New-Onset Generalized Myasthenia Gravis and Refractory Generalized Myasthenia Gravis

(2020) Susanna Brauner et al.   JAMA Neurology

Long-Lasting Rituximab-Induced Reduction of Specific—But Not Total—IgG4 in MuSK-Positive Myasthenia Gravis

(2020) Mariapaola Marino et al.   Frontiers in Immunology

Autoimmune Pathology in Myasthenia Gravis Disease Subtypes Is Governed by Divergent Mechanisms of Immunopathology

(2020) Miriam L. Fichtner et al.   Frontiers in Immunology

Efficacy and safety of rituximab in autoimmune encephalitis: A meta‐analysis

(2020) Gaurav Nepal et al.   ACTA NEUROLOGICA SCANDINAVICA

High efficacy of rituximab for myasthenia gravis: a comprehensive nationwide study in Austria

(2019) Raffi Topakian et al.   JOURNAL OF NEUROLOGY

Rituximab as induction therapy in refractory myasthenia gravis: 18 month follow-up study

(2019) Nishita Singh et al.   JOURNAL OF NEUROLOGY

Efficacy and safety of rituximab for relapsing-remitting multiple sclerosis: A systematic review and meta-analysis

(2019) Yang Hu et al.   AUTOIMMUNITY REVIEWS

Myasthenia gravis

(2019) Nils Erik Gilhus et al.   Nature Reviews Disease Primers

Effect of low-dose rituximab treatment on T- and B-cell lymphocyte imbalance in refractory myasthenia gravis

(2019) Sisi Jing et al.   JOURNAL OF NEUROIMMUNOLOGY

Stopping oral steroid-sparing agents at initiation of rituximab in myasthenia gravis

(2019) Ricardo H. Roda et al.   NEUROMUSCULAR DISORDERS

Frequency and clinical features of treatment-refractory myasthenia gravis

(2019) Jakob Rath et al.   JOURNAL OF NEUROLOGY

Low‐dose rituximab every 6 months for the treatment of acetylcholine receptor–positive refractory generalized myasthenia gravis

(2019) Jun Lu et al.   MUSCLE & NERVE

Rituximab in refractory myasthenia gravis: extended prospective study results

(2018) Grayson Beecher et al.   MUSCLE & NERVE

The impact of rituximab infusion protocol on the long-term outcome in anti-MuSK myasthenia gravis

(2018) Elena Cortés-Vicente et al.   Annals of Clinical and Translational Neurology

Responsiveness to low-dose rituximab in refractory generalized myasthenia gravis

(2017) Sisi Jing et al.   JOURNAL OF NEUROIMMUNOLOGY

10-year-outcomes after rituximab for myasthenia gravis: Efficacy, safety, costs of inhospital care, and impact on childbearing potential

(2017) Karl Stieglbauer et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Rituximab treatment of myasthenia gravis: A systematic review

(2017) Rup Tandan et al.   MUSCLE & NERVE

Rituximab as treatment for anti-MuSK myasthenia gravis

(2017) Michael K. Hehir et al.   NEUROLOGY

Resistant myasthenia gravis and rituximab: A monocentric retrospective study of 28 patients

(2017) Vadim Afanasiev et al.   NEUROMUSCULAR DISORDERS

Durability of the Rituximab Response in Acetylcholine Receptor Autoantibody–Positive Myasthenia Gravis

(2017) Kimberly R. Robeson et al.   JAMA Neurology

International consensus guidance for management of myasthenia gravis

(2016) Donald B. Sanders et al.   NEUROLOGY

Efficacy and Safety of Rituximab Therapy in Neuromyelitis Optica Spectrum Disorders

(2016) Valentina Damato et al.   JAMA Neurology

Rituximab in refractory myasthenia gravis: a prospective, open-label study with long-term follow-up

(2016) Dustin Anderson et al.   Annals of Clinical and Translational Neurology

Myasthenia gravis: subgroup classification and therapeutic strategies

(2015) Nils Erik Gilhus et al.   LANCET NEUROLOGY

Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis

(2014) Raffaele Iorio et al.   JOURNAL OF NEUROLOGY

Interleukin-10 producing-B cells and their association with responsiveness to rituximab in myasthenia gravis

(2013) Feng Sun et al.   MUSCLE & NERVE

Rituximab in refractory and non-refractory myasthenia: A retrospective multicenter study

(2012) Nicolas Collongues et al.   MUSCLE & NERVE

Long-lasting treatment effect of rituximab in MuSK myasthenia

(2012) J. Diaz-Manera et al.   NEUROLOGY

Response of patients with refractory myasthenia gravis to rituximab: a retrospective study

(2011) Richard J. Nowak et al.   Therapeutic Advances in Neurological Disorders

Rituximab for severe myasthenia gravis - experience from five patients

(2010) C. Lindberg et al.   ACTA NEUROLOGICA SCANDINAVICA

A systematic review of population based epidemiological studies in Myasthenia Gravis

(2010) Aisling S Carr et al.   BMC Neurology

Use and monitoring of low dose rituximab in myasthenia gravis

(2010) S. Blum et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome

(2010) P. Maddison et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Rituximab: Mechanism of Action

(2010) George J. Weiner   SEMINARS IN HEMATOLOGY

Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial

(2009) Joan T. Merrill et al.   ARTHRITIS AND RHEUMATISM

Rituximab for myasthenia gravis

(2009) Karl Stieglbauer et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Sustained response to Rituximab in anti-AChR and anti-MuSK positive Myasthenia Gravis patients

(2008) Isabel Illa et al.   JOURNAL OF NEUROIMMUNOLOGY